Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing

an Italian cohort study and overview of the literature

Marta Lionetti, Marzia Barbieri, Martina Manzoni, Sonia Fabris, Cecilia Bandini, Katia Todoerti, Filomena Nozza, Davide Rossi, Pellegrino Musto, Luca Baldini, Antonino Neri

Research output: Contribution to journalArticle

Abstract

The prevalence of TP53 mutations greatly varies between tumor types; in multiple myeloma (MM) they were rarely detected at presentation, while increased frequency was reported with disease progression. Using next-generation sequencing, we analyzed TP53 exons 4-9 in a large representative cohort comprising patients with MM at diagnosis and more aggressive forms of plasma cell (PC) dyscrasia, identifying mutations in 4/129 (3%) MM, 6/24 (25%) primary PC leukemia, and 2/10 (20%) secondary PC leukemia cases. A similar increase in prevalence associated with disease aggressiveness (5%, 29.2% and 44%, respectively) was observed for TP53 deletion. Interestingly, in five patients mutations were not concomitant with TP53 deletion. Furthermore, longitudinal analysis revealed the acquisition of TP53 mutations in three of nineteen cases analyzed at relapse. Identified variants were mostly missense mutations concentrated in the DNA binding domain, only partly reflecting the pattern globally observed in human cancers. Our data confirm that TP53 mutations are rare in MM at presentation and rather represent a marker of progression, similarly to del(17p); however, their occurrence even in absence of deletions supports the importance of their assessment in patients with PC dyscrasia, in terms of both risk stratification and therapeutic implications.

Original languageEnglish
Pages (from-to)21353-61
Number of pages9
JournalOncotarget
Volume7
Issue number16
DOIs
Publication statusPublished - Apr 19 2016

Fingerprint

Paraproteinemias
Multiple Myeloma
Cohort Studies
Mutation
Plasma Cell Leukemia
Missense Mutation
Disease Progression
Exons
Neoplasms
Recurrence
DNA

Keywords

  • Journal Article

Cite this

Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing : an Italian cohort study and overview of the literature. / Lionetti, Marta; Barbieri, Marzia; Manzoni, Martina; Fabris, Sonia; Bandini, Cecilia; Todoerti, Katia; Nozza, Filomena; Rossi, Davide; Musto, Pellegrino; Baldini, Luca; Neri, Antonino.

In: Oncotarget, Vol. 7, No. 16, 19.04.2016, p. 21353-61.

Research output: Contribution to journalArticle

@article{f6f06607911241f39f1cc3eea3512830,
title = "Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature",
abstract = "The prevalence of TP53 mutations greatly varies between tumor types; in multiple myeloma (MM) they were rarely detected at presentation, while increased frequency was reported with disease progression. Using next-generation sequencing, we analyzed TP53 exons 4-9 in a large representative cohort comprising patients with MM at diagnosis and more aggressive forms of plasma cell (PC) dyscrasia, identifying mutations in 4/129 (3{\%}) MM, 6/24 (25{\%}) primary PC leukemia, and 2/10 (20{\%}) secondary PC leukemia cases. A similar increase in prevalence associated with disease aggressiveness (5{\%}, 29.2{\%} and 44{\%}, respectively) was observed for TP53 deletion. Interestingly, in five patients mutations were not concomitant with TP53 deletion. Furthermore, longitudinal analysis revealed the acquisition of TP53 mutations in three of nineteen cases analyzed at relapse. Identified variants were mostly missense mutations concentrated in the DNA binding domain, only partly reflecting the pattern globally observed in human cancers. Our data confirm that TP53 mutations are rare in MM at presentation and rather represent a marker of progression, similarly to del(17p); however, their occurrence even in absence of deletions supports the importance of their assessment in patients with PC dyscrasia, in terms of both risk stratification and therapeutic implications.",
keywords = "Journal Article",
author = "Marta Lionetti and Marzia Barbieri and Martina Manzoni and Sonia Fabris and Cecilia Bandini and Katia Todoerti and Filomena Nozza and Davide Rossi and Pellegrino Musto and Luca Baldini and Antonino Neri",
year = "2016",
month = "4",
day = "19",
doi = "10.18632/oncotarget.7241",
language = "English",
volume = "7",
pages = "21353--61",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "16",

}

TY - JOUR

T1 - Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing

T2 - an Italian cohort study and overview of the literature

AU - Lionetti, Marta

AU - Barbieri, Marzia

AU - Manzoni, Martina

AU - Fabris, Sonia

AU - Bandini, Cecilia

AU - Todoerti, Katia

AU - Nozza, Filomena

AU - Rossi, Davide

AU - Musto, Pellegrino

AU - Baldini, Luca

AU - Neri, Antonino

PY - 2016/4/19

Y1 - 2016/4/19

N2 - The prevalence of TP53 mutations greatly varies between tumor types; in multiple myeloma (MM) they were rarely detected at presentation, while increased frequency was reported with disease progression. Using next-generation sequencing, we analyzed TP53 exons 4-9 in a large representative cohort comprising patients with MM at diagnosis and more aggressive forms of plasma cell (PC) dyscrasia, identifying mutations in 4/129 (3%) MM, 6/24 (25%) primary PC leukemia, and 2/10 (20%) secondary PC leukemia cases. A similar increase in prevalence associated with disease aggressiveness (5%, 29.2% and 44%, respectively) was observed for TP53 deletion. Interestingly, in five patients mutations were not concomitant with TP53 deletion. Furthermore, longitudinal analysis revealed the acquisition of TP53 mutations in three of nineteen cases analyzed at relapse. Identified variants were mostly missense mutations concentrated in the DNA binding domain, only partly reflecting the pattern globally observed in human cancers. Our data confirm that TP53 mutations are rare in MM at presentation and rather represent a marker of progression, similarly to del(17p); however, their occurrence even in absence of deletions supports the importance of their assessment in patients with PC dyscrasia, in terms of both risk stratification and therapeutic implications.

AB - The prevalence of TP53 mutations greatly varies between tumor types; in multiple myeloma (MM) they were rarely detected at presentation, while increased frequency was reported with disease progression. Using next-generation sequencing, we analyzed TP53 exons 4-9 in a large representative cohort comprising patients with MM at diagnosis and more aggressive forms of plasma cell (PC) dyscrasia, identifying mutations in 4/129 (3%) MM, 6/24 (25%) primary PC leukemia, and 2/10 (20%) secondary PC leukemia cases. A similar increase in prevalence associated with disease aggressiveness (5%, 29.2% and 44%, respectively) was observed for TP53 deletion. Interestingly, in five patients mutations were not concomitant with TP53 deletion. Furthermore, longitudinal analysis revealed the acquisition of TP53 mutations in three of nineteen cases analyzed at relapse. Identified variants were mostly missense mutations concentrated in the DNA binding domain, only partly reflecting the pattern globally observed in human cancers. Our data confirm that TP53 mutations are rare in MM at presentation and rather represent a marker of progression, similarly to del(17p); however, their occurrence even in absence of deletions supports the importance of their assessment in patients with PC dyscrasia, in terms of both risk stratification and therapeutic implications.

KW - Journal Article

U2 - 10.18632/oncotarget.7241

DO - 10.18632/oncotarget.7241

M3 - Article

VL - 7

SP - 21353

EP - 21361

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 16

ER -